Summary. This study evaluated the efficacy of allogeneic bone marrow transplantation (AlloBMT) in eight patients who had chronic lymphocytic leukaemia (CLL) in Richter's transformation. Five patients were in resistant relapse and three others were in sensitive or untreated relapse. Three out of eight patients (38%) were alive and in remission at 14 months, 47 months and 67 months respectively. Two of these three patients, including one with an unrelated-donor transplant and a prior, unsuccessful autologous transplantation, received a non-myeloablative preparative regimen. These data suggest that, compared with conventional chemotherapy, AlloBMT improves the prognosis for patients with Richter's syndrome. Further study of a larger number of patients is needed to confirm these results.
Chronic lymphocytic leukaemia (CLL) may develop disease transformation to an aggressive lymphoma, typically a diffuse large cell lymphoma (DLCL) (Armitage et al, 1978) . The resulting Richter's syndrome (RS) is typically manifested by a sudden clinical deterioration of the patient and is characterized by rapid progression of lymphadenopathy, by extranodal disease and by constitutional symptoms.
The response to conventional chemotherapy and the outcome of patients with this syndrome have been poor. At the University of Texas M.D. Anderson Cancer Center, a retrospective study of 39 patients who were treated with conventional systemic chemotherapy demonstrated a median survival of only 5 months from the time of transformation from CLL to DLCL (Robertson et al, 1993) . Only one (3%) out of 39 patients in that study remained in complete remission beyond 2 years.
In an effort to improve these results, we evaluated highdose chemotherapy followed by allogeneic bone marrow transplantation (AlloBMT) for the treatment of RS. We report here our experience with eight patients treated between 1991 and 1997.
PATIENTS AND METHODS
Patients with RS were eligible to receive high-dose chemotherapy if they had an adequate performance status (Zubrod , 2) and if they had no severe concomitant medical or psychiatric illnesses. From 1995, patients who were older than 50 years of age or who had a prior haematopoietic transplant were eligible to receive a non-ablative preparative regimen, followed by AlloBMT.
The diagnosis of RS was histologically confirmed in all cases. Disease stage was evaluated in accordance with conventional Ann Arbor criteria.
The preparative regimen varied. Prophylaxis against graft-versus-host disease (GVHD) consisted of cyclosporin and methylprednisolone in two patients, cyclosporin and methotrexate (5 mg/m 2 iv on days 1, 3 and 6) in two patients, and tacrolimus and methotrexate in three patients. One patient who received a non-ablative preparative regimen received no prophylaxis against GVHD.
Filgrastim was administered to the patients subcutaneously from d 1 until their neutrophil counts recovered to . 1 Â 10 9 /l. Prophylaxis against infection consisted of acyclovir and fluconazole plus oral quinolines or a nonabsorbable antibiotic administered to all patients during neutropenia. After their granulocyte counts recovered to . 1´0 Â 10 9 /l, patients who were seropositive for cytomegalovirus or who received a transplant from a donor who was serepositive for cytomegalovirus received prophylactic ganciclovir until d 100. Prophylaxis against Pneumocystis carinii consisted of trimethoprim/sulphamethoxazole or pentamidine for 1 year after transplant.
Response to therapy was evaluated at 1 month, 3 months and 6 months after transplantation, and then every 6 months or as clinically indicated. Survival function was estimated by the Kaplan±Meier method (Kaplan & Meier, 1958) RESULTS Between 1991 and 1997, eight patients were studied. Characteristics of the patients are shown in Table I . Patient age ranged from 38 years to 59 years, with a median age of 50 years. Five patients were men and three were women. All patients had been heavily pretreated. The median number of chemotherapeutic regimens received prior to the study was four (range, two to five). All patients, but one, had received prior fludarabine-based therapy for CLL. The interval between the initial diagnosis of CLL and documentation of RS ranged from 6 months to 186 months, with a median of 48 months. All patients had diffuse nodal transformation. Two patients had evidence of bone marrow involvement. At the time of transplant, five patients were in resistant relapse and three patients were in sensitive or untested relapse. Seven patients had stage III or IV disease, and five patients had B symptoms. Six patients received the transplant from an HLA-identical sibling. Two patients received the transplant from a matched unrelated donor; both patients had previously undergone an autologous bone marrow transplantation (ABMT).
The overall survival rate and event-free survival were 38%. Three patients are alive and continue to be in remission at 14 months, 47 months and 67 months respectively. Two of the three patients in remission, including one who received an unrelated-donor transplant after failing to respond to a prior ABMT, received a nonmyeloablative preparative regimen.
The causes of failure are shown in Table II . Five deaths occurred; all were related to toxicity. One patient died of acute GVHD. Two patients developed diffuse alveolar haemorrhage, which was associated, in one case, with Aspergillus fumigatus infection. One patient had disseminated Candida and one patient died of respiratory syncytial viral pneumonia.
DISCUSSION
Chronic lymphocytic leukaemia in Richter's transformation is associated with a dismal prognosis. The largest published study of 39 patients has been reported from the M. D. Anderson Cancer Center (Robertson et al, 1993) . When treated with conventional chemotherapy alone, the median survival of these patients was less than 5 months. The present report evaluated the outcome with allogeneic marrow or blood stem-cell transplantation for this syndrome.
The patients studied had several poor prognostic features at the time of transplantation. All were heavily pretreated; two patients had failed to respond to prior ABMTs, five patients had refractory disease, five patients had B symptoms and seven patients had stage III or IV disease. Nevertheless, after receiving AlloBMT, three patients remain alive in long-term remission.
To enhance the benefit of future therapy, it is important to identify, at an earlier stage of disease, the patients who are at risk for transformation. In that respect, waiting for the patients to develop the classical clinical symptoms is unhelpful. The development of constitutional symptoms and rapidly progressive lymphadenopathies that characterize the transformation to RS is usually a late phenomenon (Robertson et al, 1993) . Early signs of transformation might include an elevated serum lactate dehydrogenase level or a new positive uptake of tracer on gallium-67 scanning (Lorberboym et al, 1996; Partyka et al, 1999) . In a recent study from the M.D. Anderson Cancer Center, 25 patients with CLL were analysed by 67 Ga-scanning (Partyka et al, 1999) . Nine of those patients had a positive uptake. Seven out of nine patients had a subsequent biopsy that verified large-cell lymphoma. In that study, there was no correlation between the level of b 2 -microglobulin and RS.
In our limited study, there was an early mortality rate of 38% within 30 d of transplantation. The results might be improved by decreasing the toxicity of the conditioning regimen in a manner that still permits engraftment (Khouri et al, 1998) . We are encouraged by the fact that two patients who received a non-ablative preparative regimen had minimal toxicity and achieved durable remissions. One of these two patients received a transplant from an unrelated donor after failing to respond to a prior ABMT. The PFA regimen (cisplatin, fludarabine, cytarabine) was chosen as a non-ablative preparative regimen because it has been shown to have activity against RS (Giles et al, 1998) . Although this activity is only of short duration, it allows enough time for the disease to be controlled until the graft-versus-lymphoma reaction starts to operate.
In conclusion, AlloBMT might provide a better outcome than conventional chemotherapy in RS patients. The prognosis might be improved by identifying the early signs of transformation to RS when patients still have chemosensitive disease. The number of patients in the present series was small and more studies are needed to reach definitive conclusions.
